Therapeutic advances in gastroenterology
Cure8 research brief
Why This Matters
Delivery method affects daily life and adherence. If you use or may use risankizumab, the on-body injector in this study was highly acceptable to most patients and caused mostly mild, local skin reactions, which may make it a convenient maintenance option.
Who Should Pay Attention
Adults with Crohn’s disease considering or receiving risankizumab; patients on biologics interested in self-administration devices; gastroenterologists and infusion nurses.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This study reports patient-reported acceptability and short-term tolerability of risankizumab delivered with an on-body injector (OBI) in people with Crohn’s disease, based on an early-access, multicenter prospective cohort followed to 24 weeks.
The main outcome was an acceptability numerical scale (ANS); average acceptability for OBI-risankizumab was high (≈9.5/10 at baseline and stable through W24). Patients rated the OBI as more acceptable than IV infusions, pen injectors, and syringes, and 64% preferred the OBI route.
The most common adverse events were mild application-site pain and localized erythema; no discontinuations were reported for these events. The study sample included 58 patients, many with multiple prior advanced therapies; follow-up was 24 weeks. The report focuses on acceptability and tolerability rather than comparative effectiveness or long-term safety.
If you are considering risankizumab or a different self-administration device, discuss device options, training, and local-site reactions with your care team. This study suggests an OBI may be a well-liked option in the short term but does not address long-term outcomes or effectiveness.
Keep In Mind
This is an early-access, prospective cohort with 24-week follow-up and a focus on patient acceptability and short-term tolerability. It does not evaluate long-term safety, effectiveness, or comparisons of clinical outcomes between administration routes.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationTherapeutic advances in gastroenterology
AuthorsBuisson A, Gebara K, Caron B +16 more
Study typeJournal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedSep 10, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Effectiveness and Safety of Risankizumab in Crohn Disease After Failure of a First Line of Advanced Therapy: A Long-Term, Real-Life Study.
This real-world, multicenter study suggests risankizumab can induce clinical and steroid-free remission and mucosal healing in many patients with Crohn disease who previously failed advanced therapies, which may be...
Prospective real-world experience with risankizumab in difficult-to-treat Crohn’s disease: results from the Dutch Initiative on Crohn and Colitis Registry
The study provides real-world effectiveness and safety data for risankizumab in a largely difficult-to-treat Crohn's population, showing about half achieved corticosteroid-free clinical remission at 24 weeks —...
Long-Term Effectiveness and Persistence of Ustekinumab in Crohn's Disease Patients: An Observational Retrospective Study.
Ustekinumab is already approved for moderate-to-severe Crohn's disease; this real-world study reports encouraging longer-term clinical, biological, and endoscopic outcomes up to 96 weeks and suggests good treatment...